Cargando…
The long journey to bring a Myc inhibitor to the clinic
The oncogene Myc is deregulated in the majority of human tumors and drives numerous hallmarks of cancer. Despite its indisputable role in cancer development and maintenance, Myc is still undrugged. Developing a clinical inhibitor for Myc has been particularly challenging owing to its intrinsically d...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240852/ https://www.ncbi.nlm.nih.gov/pubmed/34160558 http://dx.doi.org/10.1083/jcb.202103090 |
_version_ | 1783715286315171840 |
---|---|
author | Whitfield, Jonathan R. Soucek, Laura |
author_facet | Whitfield, Jonathan R. Soucek, Laura |
author_sort | Whitfield, Jonathan R. |
collection | PubMed |
description | The oncogene Myc is deregulated in the majority of human tumors and drives numerous hallmarks of cancer. Despite its indisputable role in cancer development and maintenance, Myc is still undrugged. Developing a clinical inhibitor for Myc has been particularly challenging owing to its intrinsically disordered nature and lack of a binding pocket, coupled with concerns regarding potentially deleterious side effects in normal proliferating tissues. However, major breakthroughs in the development of Myc inhibitors have arisen in the last couple of years. Notably, the direct Myc inhibitor that we developed has just entered clinical trials. Celebrating this milestone, with this Perspective, we pay homage to the different strategies developed so far against Myc and all of the researchers focused on developing treatments for a target long deemed undruggable. |
format | Online Article Text |
id | pubmed-8240852 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-82408522022-02-02 The long journey to bring a Myc inhibitor to the clinic Whitfield, Jonathan R. Soucek, Laura J Cell Biol Perspective The oncogene Myc is deregulated in the majority of human tumors and drives numerous hallmarks of cancer. Despite its indisputable role in cancer development and maintenance, Myc is still undrugged. Developing a clinical inhibitor for Myc has been particularly challenging owing to its intrinsically disordered nature and lack of a binding pocket, coupled with concerns regarding potentially deleterious side effects in normal proliferating tissues. However, major breakthroughs in the development of Myc inhibitors have arisen in the last couple of years. Notably, the direct Myc inhibitor that we developed has just entered clinical trials. Celebrating this milestone, with this Perspective, we pay homage to the different strategies developed so far against Myc and all of the researchers focused on developing treatments for a target long deemed undruggable. Rockefeller University Press 2021-06-23 /pmc/articles/PMC8240852/ /pubmed/34160558 http://dx.doi.org/10.1083/jcb.202103090 Text en © 2021 Whitfield and Soucek http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Perspective Whitfield, Jonathan R. Soucek, Laura The long journey to bring a Myc inhibitor to the clinic |
title | The long journey to bring a Myc inhibitor to the clinic |
title_full | The long journey to bring a Myc inhibitor to the clinic |
title_fullStr | The long journey to bring a Myc inhibitor to the clinic |
title_full_unstemmed | The long journey to bring a Myc inhibitor to the clinic |
title_short | The long journey to bring a Myc inhibitor to the clinic |
title_sort | long journey to bring a myc inhibitor to the clinic |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240852/ https://www.ncbi.nlm.nih.gov/pubmed/34160558 http://dx.doi.org/10.1083/jcb.202103090 |
work_keys_str_mv | AT whitfieldjonathanr thelongjourneytobringamycinhibitortotheclinic AT souceklaura thelongjourneytobringamycinhibitortotheclinic AT whitfieldjonathanr longjourneytobringamycinhibitortotheclinic AT souceklaura longjourneytobringamycinhibitortotheclinic |